WDNA vs. FMED

Last updated Jun 5, 2026

WDNA (WisdomTree BioRevolution Fund) and FMED (Fidelity Disruptive Medicine ETF) are both Health & Biotech Equities funds. WDNA is passively managed, while FMED is actively managed. Over the past year, WDNA returned 50.50% vs 6.19% for FMED. Their correlation of 0.80 suggests significant overlap in exposure. WDNA charges 0.45%/yr vs 0.50%/yr for FMED.

Performance

WDNA vs. FMED - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in WisdomTree BioRevolution Fund (WDNA) and Fidelity Disruptive Medicine ETF (FMED). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, WDNA achieves a 8.96% return, which is significantly higher than FMED's -6.82% return.

WDNA

• 1D: 2.94%
• 1M: 2.56%
• YTD: 8.96%
• 6M: 10.44%
• 1Y: 50.50%
• 3Y*: 3.54%
• 5Y*: -4.78%
• 10Y*: —

FMED

• 1D: 2.77%
• 1M: 0.47%
• YTD: -6.82%
• 6M: -11.67%
• 1Y: 6.19%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

WDNA vs. FMED - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
WDNA WisdomTree BioRevolution Fund	8.96%	22.68%	-14.18%	-5.36%
FMED Fidelity Disruptive Medicine ETF	-6.82%	9.69%	2.29%	-4.20%

Correlation

The correlation between WDNA and FMED is 0.78, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.78
Correlation (All Time) Calculated using the full available price history since Jun 13, 2023	0.80

The correlation between WDNA and FMED has been stable across timeframes, ranging from 0.78 to 0.80 - a consistent structural relationship.

WDNA vs. FMED - Sectors Allocation Comparison

Sectors	WDNA	FMED
Healthcare	85.0%	98.0%
Basic Materials	6.5%	-
Consumer Defensive	3.0%	-
Energy	1.1%	-
Communication Services	-	-
Consumer Cyclical	-	-
Financial Services	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	1.0%
Utilities	-	-

Return for Risk

WDNA vs. FMED — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

WDNA

WDNA Risk / Return Rank: 63
WDNA Sharpe Ratio Rank: 59
WDNA Sortino Ratio Rank: 62
WDNA Omega Ratio Rank: 53
WDNA Calmar Ratio Rank: 83
WDNA Martin Ratio Rank: 57

FMED

FMED Risk / Return Rank: 14
FMED Sharpe Ratio Rank: 14
FMED Sortino Ratio Rank: 14
FMED Omega Ratio Rank: 14
FMED Calmar Ratio Rank: 13
FMED Martin Ratio Rank: 13

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

WDNA vs. FMED - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for WisdomTree BioRevolution Fund (WDNA) and Fidelity Disruptive Medicine ETF (FMED). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	WDNA	FMED	Difference
Sharpe ratio: Return per unit of total volatility	1.98	0.33	+1.65
Sortino ratio: Return per unit of downside risk	2.85	0.62	+2.22
Omega ratio: Gain probability vs. loss probability	1.32	1.07	+0.25
Calmar ratio: Return relative to maximum drawdown	4.34	0.34	+4.00
Martin ratio: Return relative to average drawdown	9.85	0.78	+9.07
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

WDNA vs. FMED - Sharpe Ratio Comparison

The current WDNA Sharpe Ratio is 1.98, which is higher than the FMED Sharpe Ratio of 0.33. The chart below compares the historical Sharpe Ratios of WDNA and FMED, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	WDNA	FMED	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.98	0.33	+1.65
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.19	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.19	0.00	-0.19

Drawdowns

WDNA vs. FMED - Drawdown Comparison

The maximum WDNA drawdown since its inception was -58.87%, which is greater than FMED's maximum drawdown of -21.84%. Use the drawdown chart below to compare losses from any high point for WDNA and FMED.

Drawdown Indicators

	WDNA	FMED	Difference
Max Drawdown Largest peak-to-trough decline	-58.87%	-21.84%	-37.03%
Max Drawdown (1Y) Largest decline over 1 year	-11.70%	-18.33%	+6.63%
Max Drawdown (3Y) Largest decline over 3 years	-38.25%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-58.87%	—	—
Current Drawdown Current decline from peak	-29.86%	-12.59%	-17.27%
Average Drawdown Average peak-to-trough decline	-35.64%	-7.04%	-28.60%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.14%	8.00%	-2.86%

Volatility

WDNA vs. FMED - Volatility Comparison

WisdomTree BioRevolution Fund (WDNA) has a higher volatility of 7.35% compared to Fidelity Disruptive Medicine ETF (FMED) at 6.19%. This indicates that WDNA's price experiences larger fluctuations and is considered to be riskier than FMED based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	WDNA	FMED	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.35%	6.19%	+1.16%
Volatility (6M) Calculated over the trailing 6-month period	16.59%	14.39%	+2.20%
Volatility (1Y) Calculated over the trailing 1-year period	25.66%	18.77%	+6.89%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.08%	18.43%	+6.65%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.07%	18.43%	+6.64%

WDNA vs. FMED - Expense Ratio Comparison

WDNA has a 0.45% expense ratio, which is lower than FMED's 0.50% expense ratio.

Dividends

WDNA vs. FMED - Dividend Comparison

WDNA's dividend yield for the trailing twelve months is around 4.19%, while FMED has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021
FMED Fidelity Disruptive Medicine ETF	0.00%	0.00%	0.46%	0.00%	0.00%	0.00%
WDNA WisdomTree BioRevolution Fund	4.19%	4.57%	0.75%	0.80%	0.38%	0.10%

Frequently Asked Questions

Can I hold both WDNA and FMED in my portfolio?

WDNA and FMED have a correlation of 0.78, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, WDNA or FMED?

WDNA has higher volatility (7.35%) compared to FMED (6.19%). In terms of maximum drawdown, WDNA dropped -58.87% vs FMED's -21.84%.

Which ETF is better, WDNA or FMED?

On 1-year performance, WDNA leads with 50.50% vs 6.19% for FMED. On fees, WDNA is cheaper at 0.45% per year. On volatility, FMED has been the lower-risk option at 6.19%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, WDNA or FMED?

Over the 1-year period, WDNA has performed better with a 50.50% return vs 6.19%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, WDNA or FMED?

WDNA is cheaper with a 0.45% expense ratio, compared with 0.50% for FMED.

Which ETF pays a higher dividend yield, WDNA or FMED?

WDNA has the higher dividend yield at 4.19%, compared with 0.00% for FMED.

What is the main difference between WDNA and FMED?

They also come from different issuers: WisdomTree and Fidelity. Their fees differ too: 0.45% for WDNA and 0.50% for FMED.

Which has better risk-adjusted returns?

WDNA currently has the higher Sharpe Ratio (1.98 vs 0.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.